(Q60629726)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16633299%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

title

Oxaliplatin combined with 5-FU in second line treatment of advanced pancreatic adenocarcinoma. Results of a phase II trial (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16633299%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

0 references

1 reference

1 reference

pancreatic adenocarcinoma

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16633299%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

author name string

Emmanuel Mitry

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16633299%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Michel Ducreux

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16633299%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Mahmoud Ould-Kaci

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16633299%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Jean-François Seitz

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16633299%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Roland Bugat

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16633299%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Jean-Luc Breau

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16633299%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Olivier Bouché

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16633299%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Pierre-Luc Etienne

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16633299%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Jean-Marie Tigaud

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16633299%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

François Morvan

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16633299%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Esteban Cvitkovic

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16633299%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Philippe Rougier

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16633299%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

publication date

1 March 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16633299%20AND%20SRC:MED&resulttype=core&format=json

Gastroenterologie Clinique et Biologique

19 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16633299%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

volume

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16633299%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16633299%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

page(s)

357-363

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16633299%20AND%20SRC:MED&resulttype=core&format=json

The National Cancer Data Base report on pancreatic cancer

19 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2806%2973188-8

7 January 2021

Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2806%2973188-8

7 January 2021

Chemotherapy prolongs survival in inoperable pancreatic carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2806%2973188-8

7 January 2021

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2806%2973188-8

7 January 2021

Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2806%2973188-8

7 January 2021

A phase II trial of biweekly high dose gemcitabine for patients with metastatic pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2806%2973188-8

7 January 2021

Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2806%2973188-8

7 January 2021

Weekly gemcitabine plus Epirubicin as effective chemotherapy for advanced pancreatic cancer: a multicenter phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2806%2973188-8

7 January 2021

A Phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2806%2973188-8

7 January 2021

Gemcitabine and oxaliplatin for metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II study.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2806%2973188-8

7 January 2021

Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2806%2973188-8

7 January 2021

Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2806%2973188-8

7 January 2021

Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2806%2973188-8

7 January 2021

Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2806%2973188-8

7 January 2021

Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2806%2973188-8

7 January 2021

Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2806%2973188-8

7 January 2021

Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2806%2973188-8

7 January 2021

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2806%2973188-8

7 January 2021

Use of the ratio of time to progression following first- and second-line therapy to document the activity of the combination of oxaliplatin with 5-fluorouracil in the treatment of colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2806%2973188-8

7 January 2021

Phase II trial of 5-fluorouracil plus eniluracil in patients with advanced pancreatic cancer: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2806%2973188-8

7 January 2021

Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2806%2973188-8

7 January 2021

Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2806%2973188-8

7 January 2021

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2806%2973188-8

7 January 2021

10.1016/S0399-8320(06)73188-8

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16633299%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference